Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$6.37 USD

6.37
2,238,320

-1.28 (-16.73%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (59 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

PRA Health (PRAH) Stock Down 2.8% Despite Q4 Earnings Beat

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the fourth quarter.

Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates

Glaukos' (GKOS) fourth-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

LHC Group (LHCG) Q4 Earnings Beat Estimates, Revenues Miss

LHC Group's (LHCG) fourth-quarter results benefit from organic growth in home health and hospice admissions.

Allscripts (MDRX) Q4 Earnings and Revenues Beat Estimates

Allscripts (MRDX) witnessed expansion in gross margin, driven by better-than-expected software revenues and consistent decline in operating expenses.

Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss

Amedisys (AMED) fourth-quarter 2020 revenues improve year over year, driven by strong growth across the Home Health and Hospice divisions.

Inogen (INGN) Q4 Earnings and Revenues Surpass Estimates

Inogen's (INGN) fourth-quarter results benefit from higher rental revenues and strength in business-to-business revenues.

Nevro (NVRO) Q4 Loss Narrower Than Estimated, Revenues Miss

Nevro's (NVRO) domestic and international revenues fell on a year-over-year basis in the fourth quarter.

Merit Medical (MMSI) Q4 Earnings and Revenues Beat Estimates

Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q4.

Masimo (MASI) Earnings and Revenues Beat Estimates in Q4

Masimo (MASI) continues to gain from its key Product segment, which witnessed solid growth in Q4.

Chemed (CHE) Q4 Earnings Miss Estimates, 2021 Outlook Dull

Chemed's (CHE) fourth-quarter 2020 revenues increased 2.1% year over year to $533.3 million.

Fresenius Medical (FMS) Q4 Earnings Beat, Revenues Miss

Fresenius Medical's (FMS) fourth-quarter earnings benefit from strength in Health Care Products segment, and performance across EMEA and Asia Pacific.

Medtronic's (MDT) Q3 Earnings Beat Estimates, Margins Fall

Medtronic (MDT) procedure volumes hurt by resurgence of COVID-19 cases despite increased demand for related diagnostics and therapies.

Integer Holdings (ITGR) Gains 2.4% Post Q4 Earnings Beat

Integer Holdings' (ITGR) fourth-quarter results reflect weak segmental performance.

Pacific Biosciences' (PACB) Sequel II Gets Deployed by LabCorp

Pacific Biosciences' (PACB) Sequel II HiFi sequencing gets utilized by LabCorp to detect SARS-COV-2 variants in the United States.

Avanos Medical (AVNS) Q4 Earnings and Revenues Top Estimates

Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the fourth quarter.

AMN Healthcare (AMN) Q4 Earnings and Revenues Beat Estimates

AMN Healthcare (AMN) gains from the Nurse and Allied Solutions segment in the fourth quarter.

Integra (IART) Q4 Earnings Top Estimates, Revenues Fall Y/Y

Integra (IART) fourth-quarter 2020 revenues fell 1.6% year over year to $388.6 million but rose 5% sequentially.

OPKO Health (OPK) Q4 Earnings and Revenues Beat Estimates

OPKO Health's (OPK) fourth-quarter results benefit from strength in diagnostics.

Repro Med Systems (KRMD) in Focus: Stock Moves 6.8% Higher

Repro Med Systems (KRMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Bruker (BRKR) Q4 Earnings Surpass Estimates, Margins Rise

Bruker's (BRKR) revenues increased 4.6% year over year to $627.5 million but declined 0.4% organically in fourth-quarter fiscal 2020.

Ecolab (ECL) Q4 Earnings In Line With Estimates, Revenues Lag

Although Ecolab's (ECL) fourth-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.

DaVita (DVA) Q4 Earnings and Revenues Fall Shy of Estimates

DaVita's (DVA) bottomline in Q4 declines year over year.

DexCom (DXCM) Q4 Earnings Match Estimates, Revenues Beat

DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth.

Pacific Biosciences (PACB) Q4 Earnings and Revenues Miss Estimates

Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.

LabCorp (LH) Q4 Earnings Beat Estimates, Margins Expand

LabCorp's (LH) 2021 guidance projects significant downfall in COVID-related testing revenues.